The company’s continued growth in revenue can be attributed to product penetration and continued expansion of a direct sales force. Bacterin expects to see continued revenue growth acceleration with its expanded sales force and two recently launched biologics scaffolds: Osteosponge SC and hMatrix.
Read the company news release about Bacterin’s first quarter financial results.
Related Articles on Device Company Financial Results:
SANUWAVE Posts Q1 $252K Revenue, 76% Increase
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
